A Phase I Trial of SON-1010, a Tumor-Targeted, Interleukin-12-Linked, Albumin-Binding Cytokine, Shows Favorable Pharmacokinetics, Pharmacodynamics, and Safety in Healthy VolunteersDownload
A Phase I Trial of SON-1010, a Tumor-Targeted, Interleukin-12-Linked, Albumin-Binding Cytokine, Shows Favorable Pharmacokinetics, Pharmacodynamics, and Safety in Healthy VolunteersDownload